Effect of Recombinant ApoA-I Milano on Coronary Atherosclerosis in Patients With Acute Coronary Syndromes

20031,704 citationsJournal Articlehybrid Open Access

Authors

Steven E. Nissen · Cleveland Clinic

Taro Tsunoda · Toho University

E. Murat Tuzcu · Cleveland Clinic

Paul Schoenhagen · Cleveland Clinic

Christopher B. Cooper · Children’s Village

Muhammad Yasin · INTEGRIS Baptist Medical Center

Gregory M. Eaton ·

Abstract

A recombinant ApoA-I Milano/phospholipid complex (ETC-216) administered intravenously for 5 doses at weekly intervals produced significant regression of coronary atherosclerosis as measured by IVUS. Although promising, these results require confirmation in larger clinical trials with morbidity and mortality end points.

Topics & Keywords

Lipoproteins and Cardiovascular Health Diabetes, Cardiovascular Risks, and Lipoproteins Adipokines, Inflammation, and Metabolic Diseases

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: JAMA

Volume 290, Issue 17, pp. 2292-2292

DOI: 10.1001/jama.290.17.2292

Field-Weighted Citation Impact: 126.10